Xie Xinhua, Xiong Zhenchong, Li Xing, Huang Xiaojia, Ye Feng, Tang Hailin, Xie Xiaoming
Laboratory of Oncology in South China, Department of Breast Oncology, State Key Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China.
Front Oncol. 2019 Nov 8;9:1193. doi: 10.3389/fonc.2019.01193. eCollection 2019.
Numerous studies have showed that internal mammary lymph node (IMLN) metastasis is an important adverse prognostic factor in patients with breast cancer (BC), however, there are no available prediction model for the preoperative diagnosis of IMLN metastasis. Data from 102 breast cancer patients treated with IMLN operation were used to establish and calibrate a nomogram for IMLN status based on multivariate logistic regression. Prediction performance of this model was further validated with a second set of 50 patients with BC. Discrimination of the predict model was assessed by the C-index, and calibration assessed by calibration plots. Moreover, we conducted the decision curve analysis (DCA) to evaluate the clinical value of the nomogram. Finally, the survival status of patients in different risk groups based on nomogram were also compared. The final multivariate regression model included tumor location, lymph vascular invasion (LVI), and pathological axillary lymph node stage (pALN stage). A nomogram was developed as a graphical representation of the model and had good calibration and discrimination in both sets (with C-index of 0.86 and 0.83 for the training and validation set, respectively). Moreover, the DCA showed the clinical usefulness of our constructed nomogram. False negative (FN) in low risk group classified by nomogram (FN-LR-nomogram) did not significantly impact adjuvant treatment decision making, and more importantly, patients with FN-LR-nomogram had recurrence-free survival equivalent to patients with pathologically ture negative in low risk group classified by nomogram (TN-LR-nomogram). As a non-invasive prediction tool, our nomogram shows favorable predictive accuracy for IMLN metastasis in patients with BC and can serve as a basis to integrate future molecular markers for its clinical application.
大量研究表明,内乳淋巴结(IMLN)转移是乳腺癌(BC)患者重要的不良预后因素,然而,目前尚无用于术前诊断IMLN转移的预测模型。我们使用102例行IMLN手术的乳腺癌患者的数据,基于多因素逻辑回归建立并校准了一个预测IMLN状态的列线图。该模型的预测性能在另一组50例BC患者中进一步得到验证。通过C指数评估预测模型的区分度,通过校准图评估校准情况。此外,我们进行了决策曲线分析(DCA)以评估列线图的临床价值。最后,还比较了基于列线图的不同风险组患者的生存状况。最终的多因素回归模型包括肿瘤位置、淋巴管侵犯(LVI)和病理腋窝淋巴结分期(pALN分期)。开发了一个列线图作为该模型的图形表示,在两组中均具有良好的校准和区分度(训练集和验证集的C指数分别为0.86和0.83)。此外,DCA显示了我们构建的列线图的临床实用性。列线图分类的低风险组中的假阴性(FN)对辅助治疗决策没有显著影响,更重要的是,列线图分类的低风险组中FN-LR-列线图患者的无复发生存期与列线图分类的低风险组中病理真阴性(TN-LR-列线图)患者相当。作为一种非侵入性预测工具,我们的列线图对BC患者的IMLN转移显示出良好的预测准确性,可为整合未来分子标志物用于临床应用提供依据。